How are you managing patients with H&N cancers meriting definitive concurrent chemoRT during cisplatin shortages?

If cisplatin cannot be used, other systemic therapies should be considered. The NCCN guidelines list various regimens, as noted below. Given the improvements in the delivery and quality of radiation therapy, I am a believer that single agent carboplatin (AUC 6 Q 3 weeks or AUC 2 Q weekly) can be sub...

Interesting and appropriate question. A few thoughts regarding cisplatin shortage

1. This situation may have passed, and it looks like most institutions have been able to procure enough supply. The first step would be to check with institutional supply.
2. Set up institutional committees to review cisplat...

I am surprised single agent docetaxel is not mentioned as an option.

There is a recent RCT from Tata Memorial Hospital showing a survival benefit in patients with HNC that were not cisplatin candidates. There was a 9% survival benefit noted at 2 years. The data for this regimen seems stronger than t...